MedPath

Acthar

These highlights do not include all the information needed to use ACTHAR® GEL safely and effectively. See full prescribing information for ACTHAR GEL. ACTHAR GEL (repository corticotropin injection), for intramuscular or subcutaneous use. Initial U.S. Approval: 1952

Approved
Approval ID

7b48ddec-e815-45f4-9ca0-5c0daaf56f30

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 11, 2023

Manufacturers
FDA

Mallinckrodt ARD LLC

DUNS: 625130828

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Repository Corticotropin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63004-8710
Application NumberNDA008372
Product Classification
M
Marketing Category
C73594
G
Generic Name
Repository Corticotropin
Product Specifications
Route of AdministrationINTRAMUSCULAR, SUBCUTANEOUS
Effective DateJune 30, 2023
FDA Product Classification

INGREDIENTS (7)

CORTICOTROPINActive
Quantity: 80 [USP'U] in 1 mL
Code: K0U68Q2TXA
Classification: ACTIB
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327L
Classification: IACT
PHENOLInactive
Code: 339NCG44TV
Classification: IACT
CYSTEINEInactive
Code: K848JZ4886
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
ACETIC ACIDInactive
Code: Q40Q9N063P
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Acthar - FDA Drug Approval Details